Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

CPC-111 clinical results presented at congress

Nov. 1, 1996

Na+ channel inhibitor as cardioprotectant

Nov. 1, 1996

Tyrosine kinase inhibitor for restenosis

Nov. 1, 1996

VasoCare therapy for hypertension

Nov. 1, 1996

New dual ACE/NEP inhibitors claimed by Bristol-Myers Squibb

Nov. 1, 1996

Ono discloses cGMP-PDE/TxA2 synthase inhibitors

Nov. 1, 1996

Anti-TNF MAb effective in treating septic shock in two major studies

Oct. 25, 1996

Progress on Neuprex for hemorrhagic trauma

Oct. 25, 1996

cGMP PDE inhibitors reported by DuPont Merck

Oct. 25, 1996

AM-140 available for licensing

Oct. 25, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...